As of May 28, 2025, Xbrane Biopharma AB (XBRANE.ST) reports a ROE (Return on Equity) of -127.66%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Xbrane Biopharma AB's ROE (Return on Equity)
Over recent years, Xbrane Biopharma AB's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -127.66% |
| 2023-12-31 | -226.56% |
| 2022-12-31 | -40.60% |
| 2021-12-31 | -43.63% |
| 2020-12-31 | -87.71% |
This slight upward trend highlights how Xbrane Biopharma AB manages its efficiency in generating profits from shareholders' equity over time.
Comparing Xbrane Biopharma AB's ROE (Return on Equity) to Peers
To better understand Xbrane Biopharma AB's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Xbrane Biopharma AB (XBRANE.ST) | -127.66% |
| Aegirbio AB (AEGIR.ST) | 4108.47% |
| Biophytis SA (ALBPS.PA) | 441.43% |
| Faron Pharmaceuticals Oy (FARN.L) | 265.52% |
| Kiadis Pharma NV (KDS.AS) | 248.91% |
| Scancell Holdings PLC (SCLP.L) | 167.16% |
Compared to its competitors, Xbrane Biopharma AB's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.